These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6377569)

  • 1. Registry of Prospective Clinical Trials--Sixth Report.
    Verstraete M
    Thromb Haemost; 1984 Apr; 51(2):283-90. PubMed ID: 6377569
    [No Abstract]   [Full Text] [Related]  

  • 2. Registry of prospective clinical trials--fifth report.
    Verstraete M
    Thromb Haemost; 1982 Dec; 48(3):334-8. PubMed ID: 6761891
    [No Abstract]   [Full Text] [Related]  

  • 3. ICTH(International Committee on Haemostasis and Thrombosis)--Sub committee on Clinical Trials. Registry of Multicenter Clinical Trials. Seventh Report--1985.
    Boissel JP
    Thromb Haemost; 1986 Apr; 55(2):282-91. PubMed ID: 3487136
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of coronary arteriosclerosis and its complications].
    Giordano MP; Allegri M
    Clin Ter; 1972 Feb; 60(3):259-74. PubMed ID: 4665993
    [No Abstract]   [Full Text] [Related]  

  • 5. Sounding Boards. Let's not let the genie escape from the bottle--again.
    Muller JE; Stone PH; Markis JE; Braunwald E
    N Engl J Med; 1981 May; 304(21):1294-6. PubMed ID: 6783909
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical aspects of thrombolytic therapy].
    Schmutzler R
    Internist (Berl); 1969 Jan; 10(1):21-9. PubMed ID: 4906437
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thrombolytic agents and substances with "minor fibrinolytic" effect].
    Verstraete M; Amery A
    Rev Atheroscler (Paris); 1968; 10(2):21-7. PubMed ID: 5759946
    [No Abstract]   [Full Text] [Related]  

  • 8. [Thrombolytic therapy. I. Introduction and principles of therapy. Indications. Contraindications. Schematics of the treatment].
    Sterkowicz S
    Przegl Lek; 1969; 25(8):565-8. PubMed ID: 4897431
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of evolving myocardial infarction by intracoronary thrombolysis and subsequent aorta-coronary bypass.
    Krebber HJ; Mathey D; Kuck KJ; Kalmar P; Rodewald G
    J Thorac Cardiovasc Surg; 1982 Feb; 83(2):186-93. PubMed ID: 6977071
    [No Abstract]   [Full Text] [Related]  

  • 10. Newer fibrinolytic agents.
    Cliffton EE
    Vasc Dis; 1966 Apr; 3(2):75-83. PubMed ID: 4222874
    [No Abstract]   [Full Text] [Related]  

  • 11. [The use of thrombolytin in the treatment o thromboses of peripheral vessels].
    Bogomolova LG; Grsbenshchikova LA; Izmaĭlova EF; Kotovshchikova MA
    Vestn Khir Im I I Grek; 1966 Jun; 96(6):3-6. PubMed ID: 6000581
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical effectiveness of a new thrombolytic preparation, Streptodecase].
    Cazov EI; Mazajev AV
    Cas Lek Cesk; 1985 Jan; 124(1):4-9. PubMed ID: 3967264
    [No Abstract]   [Full Text] [Related]  

  • 13. International committee communications. Registry of prospective clinical trials. Third report.
    Verstraete M
    Thromb Haemost; 1978 Jun; 39(3):759-67. PubMed ID: 309193
    [No Abstract]   [Full Text] [Related]  

  • 14. [Limitation of the size of the myocardial infarct by using intracoronary streptokinase administration].
    Rentrop KP; Smith H; Blanke H; Gorlin R; Chalmers T
    Ter Arkh; 1982; 54(11):18-21. PubMed ID: 6760434
    [No Abstract]   [Full Text] [Related]  

  • 15. [The present status of fibrinolytic therapy].
    Koller F
    Bull Schweiz Akad Med Wiss; 1973 Nov; 29(4):263-75. PubMed ID: 4771353
    [No Abstract]   [Full Text] [Related]  

  • 16. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
    Poston RS; White C; Gu J; Brown J; Gammie J; Pierson RN; Lee A; Connerney I; Avari T; Christenson R; Tandry U; Griffith BP
    Ann Thorac Surg; 2006 Jan; 81(1):104-10; discussion 110-1. PubMed ID: 16368345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding indications for thrombolytic therapy.
    Dietz T; Talley JD; Hiller C; Golper TA
    J Ark Med Soc; 1995 Oct; 92(5):240-3. PubMed ID: 8522500
    [No Abstract]   [Full Text] [Related]  

  • 18. The present place of fibrinolytic therapy.
    Sharp AA
    Ann R Coll Surg Engl; 1971 Jan; 48(1):27-8. PubMed ID: 5572220
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationale for testing thrombolysis in acute ischaemic stroke. MAST Group.
    Hommel M; Cornu C
    Clin Trials Metaanal; 1993 Nov; 28(6):345-56. PubMed ID: 10172266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
    Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
    J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.